ImprimisRx Announces Leadership Changes

Core Insights - Harrow has announced leadership changes at its subsidiary ImprimisRx, appointing Frank Mullery as CEO and Bridseida Cruz as Head of Quality [2][5] Leadership Appointments - Frank Mullery brings over 20 years of experience in healthcare and pharmaceuticals, having previously served as President of Sintetica US and held senior roles at STI Pharma and Mylan, where he led significant revenue growth and product launches [3] - Bridseida Cruz has over 25 years of experience in quality and operations, known for her work in FDA remediation and operational efficiencies, including launching a new FDA-registered compounding facility that improved throughput by 20% [4] Company Vision - Harrow's CEO Mark L. Baum expressed confidence in the new leadership, emphasizing the importance of fulfilling unmet needs in U.S. eyecare and positioning ImprimisRx as a leader in ophthalmic compounding [5] Company Overview - Harrow, Inc. is a leading provider of ophthalmic disease management solutions in North America, focusing on safe, effective, and affordable medications for various eye conditions [6]